Boston Scientific Holds To Year-Long Guidance Despite Weak Sales In August
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific attributes lower than expected stent sales in August to Johnson & Johnson/Cordis' increased stent supply capacity rather than the European launch of Medtronic's Endeavor drug-eluting stent